Results 121 to 130 of about 27,407 (265)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin‐dependent protein kinase IIδ in a murine model of acute doxorubicin‐related cardiotoxicity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder, Anna‐Maria Pfützenreuter, Lea Maria Funke, Maria Johanna Baier, Daniel Tarnowski, Laura Stengel, Lars Siegfried Maier, Can Martin Sag   +7 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Prurigo pigmentosa in patient with diabetes on SGLT2 inhibitor. [PDF]

JAAD Case Rep
Khan T, Hirsch Y, McGivney R, Hoyer S.
europepmc   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Bibliometric analysis of SGLT2 inhibitor treatment for diabetic kidney disease. [PDF]

Ren Fail
Hu D, Chen L, Mai R, Gao T, Guan B.
europepmc   +1 more source

Clinical characteristics and in‐hospital mortality among insulin pump users with acute coronary syndrome in the predominantly open‐loop era: A UK‐wide MINAP registry analysis

Diabetic Medicine, EarlyView.
Abstract Background We compared characteristics of adults with insulin‐treated diabetes using continuous subcutaneous insulin infusion (CSII) versus multiple daily insulin injections (MDI) during admission with acute coronary syndrome (ACS) and identified factors associated with in‐hospital mortality among CSII users.
Harshal Deshmukh, Moosa Shaikh, Emma G. Wilmot, Eric Kilpatrick, Sudipta Chattopadhyay, Thozhukat Sathyapalan, Joseph John   +6 more
wiley   +1 more source

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor-Associated Ketoacidosis Case Reports. [PDF]

Acta Anaesthesiol Scand
Snel LIP, Li X, Jamaludin F, Siegelaar SE, Holleman F, Vriesendorp TM, DeVries JH, Hoekstra JBL, Preckel B, van Raalte DH, Hermanides J, Hulst AH.   +11 more
europepmc   +1 more source

It's a game changer in terms of diabetic management’: A qualitative study of adolescents' and parents' experiences of a 6‐month trial of continuous glucose monitoring in type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando, Alexia S. Peña, Ashlee King, Melissa Oxlad   +3 more
wiley   +1 more source

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J. Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, Luke Sheridan Rains, Amanda I. Adler, Lesley Owen   +12 more
wiley   +1 more source